Global NAMPT Inhibitor Market Size is predicted to grow with a 10.9% CAGR during the forecast period for 2025-2034.
A NAMPT (nicotinamide phosphoribosyltransferase) inhibitor is a pharmaceutical agent that interferes with the function of the NAMPT enzyme, essential for the synthesis of NAD+ (nicotinamide adenine dinucleotide) within cells. NAMPT inhibitors are under investigation as potential cancer treatments, especially for tumors exhibiting elevated NAMPT expression, as they can interfere with cancer cell metabolism and induce apoptosis. The NAMPT inhibitor market is expected to increase significantly as a result of a number of growth factors. The demand for innovative treatment approaches is urgent due to the increase in prevalence of metabolic diseases and cancer.
Furthermore, a strong pipeline of NAMPT inhibitors is being produced as a result of pharmaceutical companies' increasing spending on research and development, with numerous candidates progressing through different phases of clinical trials. Additionally, interest in NAMPT inhibitors has increased due to a greater understanding of the role that NAD+ metabolism plays in cellular processes. Targeting NAMPT as a therapeutic approach has gained traction as researchers reveal the complex relationships between NAD+ levels and illnesses, drawing substantial funding and industry-academia collaboration.
However, one of the main obstacles in the NAMPT inhibitor market is the intricacy of the medication development process, which frequently results in expensive and time-consuming procedures. The Tufts Centre for the Study of Medicine Development estimates that the average cost of bringing a new medicine to market exceeds $2.6 billion and that development takes more than ten years. In the field of NAMPT inhibitors, these issues may discourage investment and reduce the rate of innovation. Furthermore, targeting metabolic pathways presents considerable obstacles because of regulatory barriers and safety concerns.
Some Major Key Players In The NAMPT Inhibitor Market are:
The NAMPT Inhibitor market is segmented based on molecule type, line of treatment, indication, route of administration, and therapeutic area. The molecule type segment consists of Small Molecules and Biologics. By line of treatment, the market is segmented into 1st Line and 2nd Line. By indication, the market segmentation includes Acute Respiratory Distress Syndrome, Acute Myeloid Leukemia, Non-Hodgkin Lymphoma, and Hodgkin Lymphoma. As per the route of administration, the market is segmented into Oral and Intravenous. By therapeutic area, the market is segmented into Respiratory Disorders and Oncological.
The small molecules is expected to hold a major global market share in 2024 due to its oral bioavailability, cell permeability, and proven track record in small-molecule drug development. Because they efficiently lower cellular NAD? levels, which cause cancer cell death, small molecule NAMPT inhibitors are being actively explored for oncology purposes, especially in hematologic malignancies and solid tumours. Medicinal chemistry developments have further improved their bioavailability and decreased off-target effects, which has increased their appeal for clinical development. Additionally, the market penetration of small molecule NAMPT inhibitors is being accelerated by the growing number of clinical trials that are being funded by industry and academic players.
The market for NAMPT inhibitors is led by the oncological sub-segment due to the rising incidence of various cancer types globally. Lung, breast, prostate, and other cancers are among the many that NAMPT inhibitors are showing great promise in treating. By blocking the NAMPT enzyme, which is essential for cancer cells to synthesize NAD+, these inhibitors aid in lowering the size and growth of tumours. For cancer cells to proliferate and survive, NAD+ production is essential. Through the inhibition of the NAD+ production pathway, NAMPT inhibitors can either effectively kill cancer cells or increase their susceptibility to chemotherapy. NAMPT inhibitors' capacity to overcome medication resistance in specific malignancies is another important element driving the oncological segment.
The North American NAMPT Inhibitor market is expected to register the highest market share in revenue in the near future because it has a large number of pharmaceutical businesses, a sophisticated healthcare system, and substantial R&D spending. Additionally, the region's emphasis on cancer research and the creation of innovative treatments is propelling the use of NAMPT inhibitors. The continuous developments in pharmaceutical and biotechnology research are another factor contributing to the expansion of the North American NAMPT inhibitor market.
In addition, Europe is projected to grow rapidly in the global NAMPT Inhibitor market. Increased investment in biotechnology research, improved healthcare infrastructure, and the rising incidence of metabolic diseases and cancer are key factors driving the growth of the NAMPT inhibitor market. With significant investments in R&D and an increasing emphasis on creative healthcare solutions.
|
Report Attribute |
Specifications |
|
Growth Rate CAGR |
CAGR of 10.9% from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ Mn and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Molecule Type, Line Of Treatment, Indication, Route Of Administration, And Therapeutic Area |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
Antengene Therapeutics, Aqualung Therapeutics, Onxeo, and Karyopharm Therapeutics. |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global NAMPT Inhibitor Market Snapshot
Chapter 4. Global NAMPT Inhibitor Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2025-2034
4.8. Global NAMPT Inhibitor Market Penetration & Growth Prospect Mapping (US$ Mn), 2024-2034
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2024)
4.10. Use/impact of AI on NAMPT INHIBITOR MARKET Industry Trends
Chapter 5. NAMPT Inhibitor Market Segmentation 1: By Molecule, Estimates & Trend Analysis
5.1. Market Share by Molecule, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Molecule:
5.2.1. Small Molecules
5.2.2. Biologics
Chapter 6. NAMPT Inhibitor Market Segmentation 2: By Therapeutic Area, Estimates & Trend Analysis
6.1. Market Share by Therapeutic Area, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Therapeutic Area:
6.2.1. Oncological
6.2.2. Respiratory Disorders
Chapter 7. NAMPT Inhibitor Market Segmentation 3: By Indication, Estimates & Trend Analysis
7.1. Market Share by Indication, 2024 & 2034
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Indication:
7.2.1. Non-Hodgkin Lymphoma
7.2.2. Hodgkin Lymphoma
7.2.3. Acute Respiratory Distress Syndrome
7.2.4. Acute Myeloid Leukemia
Chapter 8. NAMPT Inhibitor Market Segmentation 4: By Route of Administration, Estimates & Trend Analysis
8.1. Market Share by Route of Administration, 2024 & 2034
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Route of Administration:
8.2.1. Oral
8.2.2. Intravenous
Chapter 9. NAMPT Inhibitor Market Segmentation 5: By Line of Treatment, Estimates & Trend Analysis
9.1. Market Share by Line of Treatment, 2024 & 2034
9.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Line of Treatment:
9.2.1. 1st Line
9.2.2. 2nd Line
Chapter 10. NAMPT Inhibitor Market Segmentation 6: Regional Estimates & Trend Analysis
10.1. Global NAMPT Inhibitor Market, Regional Snapshot 2024 & 2034
10.2. North America
10.2.1. North America NAMPT Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
10.2.1.1. US
10.2.1.2. Canada
10.2.2. North America NAMPT Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Molecule, 2021-2034
10.2.3. North America NAMPT Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2021-2034
10.2.4. North America NAMPT Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
10.2.5. North America NAMPT Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
10.2.6. North America NAMPT Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Line of Treatment, 2021-2034
10.3. Europe
10.3.1. Europe NAMPT Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
10.3.1.1. Germany
10.3.1.2. U.K.
10.3.1.3. France
10.3.1.4. Italy
10.3.1.5. Spain
10.3.1.6. Rest of Europe
10.3.2. Europe NAMPT Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Molecule, 2021-2034
10.3.3. Europe NAMPT Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2021-2034
10.3.4. Europe NAMPT Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
10.3.5. Europe NAMPT Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
10.3.6. Europe NAMPT Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Line of Treatment, 2021-2034
10.4. Asia Pacific
10.4.1. Asia Pacific NAMPT Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
10.4.1.1. India
10.4.1.2. China
10.4.1.3. Japan
10.4.1.4. Australia
10.4.1.5. South Korea
10.4.1.6. Hong Kong
10.4.1.7. Southeast Asia
10.4.1.8. Rest of Asia Pacific
10.4.2. Asia Pacific NAMPT Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Molecule, 2021-2034
10.4.3. Asia Pacific NAMPT Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2021-2034
10.4.4. Asia Pacific NAMPT Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
10.4.5. Asia Pacific NAMPT Inhibitor Market Revenue (US$ Million) Estimates and Forecasts By Route of Administration, 2021-2034
10.4.6. Asia Pacific NAMPT Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Line of Treatment, 2021-2034
10.5. Latin America
10.5.1. Latin America NAMPT Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
10.5.1.1. Brazil
10.5.1.2. Mexico
10.5.1.3. Rest of Latin America
10.5.2. Latin America NAMPT Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Molecule, 2021-2034
10.5.3. Latin America NAMPT Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2021-2034
10.5.4. Latin America NAMPT Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
10.5.5. Latin America NAMPT Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
10.5.6. Latin America NAMPT Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Line of Treatment, 2021-2034
10.6. Middle East & Africa
10.6.1. Middle East & Africa NAMPT Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
10.6.1.1. GCC Countries
10.6.1.2. Israel
10.6.1.3. South Africa
10.6.1.4. Rest of Middle East and Africa
10.6.2. Middle East & Africa NAMPT Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Molecule, 2021-2034
10.6.3. Middle East & Africa NAMPT Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2021-2034
10.6.4. Middle East & Africa NAMPT Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
10.6.5. Middle East & Africa NAMPT Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
10.6.6. Middle East & Africa NAMPT Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Line of Treatment, 2021-2034
Chapter 11. Competitive Landscape
11.1. Major Mergers and Acquisitions/Strategic Alliances
11.2. Company Profiles
11.2.1. Antengene Therapeutics
11.2.1.1. Business Overview
11.2.1.2. Key Product/Service
11.2.1.3. Financial Performance
11.2.1.4. Geographical Presence
11.2.1.5. Recent Developments with Business Strategy
11.2.2. Aqualung Therapeutics
11.2.3. Karyopharm Therapeutics
11.2.4. OncoTartis
11.2.5. Onxeo
Segmentation of NAMPT Inhibitor Market-
NAMPT Inhibitor Market By Molecule Type-
NAMPT Inhibitor Market By Line of Treatment-
NAMPT Inhibitor Market By Indication-
NAMPT Inhibitor Market By Route of Administration-
NAMPT Inhibitor Market By Therapeutic Area-
NAMPT Inhibitor Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
